促红细胞生成素功能性rs1617640基因多态性不影响外周动脉疾病患者的预期寿命。
The Functional Erythropoetin rs1617640 Gene Polymorphism does not Affect Life Expectancy of Patients with Peripheral Arterial Disease.
作者信息
Renner Wilfried, Langsenlehner Uwe, Langsenlehner Tanja
机构信息
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036 Graz, Austria.
Internal Outpatient Department, Prodoc Plus, 8036 Graz, Austria.
出版信息
Rev Cardiovasc Med. 2023 Jul 13;24(7):199. doi: 10.31083/j.rcm2407199. eCollection 2023 Jul.
BACKGROUND
A common functional variant (c.-1306A C, rs1617640) in the gene encoding erythropoietin () has been linked to expression of erythropoietin and markers of erythropoiesis. Aim of the current study was the analysis of the role of this polymorphism for long term survival of patients with peripheral arterial disease (PAD).
METHODS
genotypes as well as biomarkers for erythropoiesis were analyzed in a cohort of 946 patients with PAD. Survival follow-up was performed 20 years af-ter recruitment of patients.
RESULTS
Twenty years after recruitment, 752 (79.5%) patients were dead, 103 (10.9%) were still alive, and 91 (9.6%) were lost-to-follow up. In a Cox regression analysis including smoking habit, sex, type-2 diabetes, hypercholesterolemia and arterial hypertension, genotypes were not associated with overall survival (Hazard ratio 0.63; 95% confidence interval 0.88-1.08, = 0.63).
CONCLUSIONS
The functional rs1617640 gene polymorphism, irrespective of its association with markers of erythropoiesis, does not affect survival of PAD patients.
背景
促红细胞生成素（EPO）编码基因中的一种常见功能变异（c.-1306A＞C，rs1617640）与促红细胞生成素的表达及红细胞生成标志物有关。本研究的目的是分析这种多态性对外周动脉疾病（PAD）患者长期生存的作用。
方法
对946例PAD患者队列进行EPO基因型以及红细胞生成生物标志物分析。在患者入组20年后进行生存随访。
结果
入组20年后，752例（79.5%）患者死亡，103例（10.9%）仍存活，91例（9.6%）失访。在一项包括吸烟习惯、性别、2型糖尿病、高胆固醇血症和动脉高血压的Cox回归分析中，EPO基因型与总生存无关（风险比0.63；95%置信区间0.88 - 1.08，P = 0.63）。
结论
功能性EPO rs1617640基因多态性，无论其与红细胞生成标志物的关联如何，均不影响PAD患者的生存。
Zotero 插件